Breaking News Instant updates and real-time market news.

TXMD

TherapeuticsMD

$5.03

-0.6 (-10.66%)

11:50
07/17/17
07/17
11:50
07/17/17
11:50

TherapeuticsMD provided no clear plan for TX-004HR, STAT says

This morning's update from TherapeuticsMD provided no clear path forward for TX-004HR, the company's estrogen therapy for postmenopausal women, STAT's Adam Feuerstein says. The stock in late morning trading is down 11% to $5.01. Reference Link

TXMD TherapeuticsMD
$5.03

-0.6 (-10.66%)

06/13/17
JEFF
06/13/17
NO CHANGE
JEFF
TherapeuticsMD could use data to push post-approval study, says Jefferies
Jefferies analyst Matthew Andrews says that TherapeuticsMD could use prior data - including a finding that low-dose vaginal estrogen is safe for women with breast cancer and a finding that estrogen delivered in a patch is safe for two years - to convince an FDA panel to allow the company to address concerns raised in a complete response letter for its TX-004 drug with a post-approval study instead of a pre-approval study. Andrews keeps a $15 price target and a buy rating on the shares.
05/23/17
STFL
05/23/17
NO CHANGE
Target $20
STFL
Buy
TherapeuticsMD scheduled to meet FDA on June 14, says Stifel
Stifel analyst Annabel Samimy says TherapeuticsMD's Type A meeting with the FDA to discuss last month's Complete Response Letter is scheduled for June 14. The analyst sees two likely scenarios from the meeting. The first has TherapeuticsMD seeking class labeling with a Phase 4 post-marketing study to eventually amend the label. And the second has the company seeking an appeal should FDA hold firm in the 12-month safety requirement to justify a differentiated label. Samimy is "convinced" that TX-004HR remains approvable and she keeps a Buy rating on the shares with a $20 price target.
05/09/17
JEFF
05/09/17
NO CHANGE
Target $15
JEFF
Buy
TherapeuticsMD price target lowered to $15 from $18 at Jefferies
Jefferies analyst Matthew Andrews lowered his price target for TherapeuticsMD to $15 citing a lower probability of success for TX-004HR following the Complete Response Letter. The analyst, with a 55% probability of approval now, believes the FDA's endometrial safety concerns appear addressable. If FDA agrees to approve '004 with a post-approval study, it could obtain a class label with boxed warning, Andrews tells investors in a research note. He keeps a Buy rating on TherapeuticsMD.
05/09/17
OPCO
05/09/17
DOWNGRADE
OPCO
Perform
TherapeuticsMD downgraded to Perform from Outperform at Oppenheimer
Oppenheimer analyst Jay Olson downgraded TherapeuticsMD to Perform saying he's surprised by the FDA's request for long-term safety data. The analyst prefers to move to the sidelines amid uncertainty resulting from the Complete Response Letter.

TODAY'S FREE FLY STORIES

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.